1. Grace Colón Succeeds Amy Abernethy on the CareDx Board

    Grace Colón Succeeds Amy Abernethy on the CareDx Board

    (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Grace Colón, Ph.D. has joined CareDx's Board of Directors...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      Board Recruitment Publication, BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content

    1. Dr. Colón brings over 25 years of experience in biopharma, genomics, healthcare and industrial biotechnology and has committed the last 6 years to developing transformative therapies for cardiac conditions. Her contributions will be invaluable as we further develop the CareDx product pipeline.
    2. I am excited to work with the CareDx management team and board at a time of tremendous growth and innovation and delighted to have the opportunity to contribute to the mission of improving transplant patient outcomes.
  3. Topics Mentioned